ProfileGDS5678 / 1441111_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 21% 19% 34% 19% 19% 19% 18% 19% 18% 19% 19% 19% 20% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5305821
GSM967853U87-EV human glioblastoma xenograft - Control 22.4623719
GSM967854U87-EV human glioblastoma xenograft - Control 32.784834
GSM967855U87-EV human glioblastoma xenograft - Control 42.401319
GSM967856U87-EV human glioblastoma xenograft - Control 52.4005219
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5124219
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4726118
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4344919
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4181518
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4446419
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4473419
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4289319
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4650820
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.450319